Bing Xu
Impact in
- Hematology top 2%
- Acute Myeloid Leukemia Research
- Cancer Research top 5%
- Cancer-related molecular mechanisms research
- Cancer, Hypoxia, and Metabolism
Papers in
-
- Histone Deacetylase Inhibitors Research 14
- Protein Degradation and Inhibitors 11
- Cell death mechanisms and regulation 9
- Oncology 31
- CAR-T cell therapy research 9
- Co-authors
- Weiguang Wang (14 shared papers)Angel L. Armesilla (3 shared papers)John L. Darling (3 shared papers)Vinodh Kannappan (3 shared papers)Jie Zha (22 shared papers)Manman Deng (24 shared papers)Ning Dong (6 shared papers)Nga Chi Yip (2 shared papers)
- Journals
- Blood (16 papers)Oncotarget (5 papers)Scientific Reports (5 papers)Experimental Cell Research (4 papers)Investigative Ophthalmology & Visual Science (4 papers)
- Partner nations
- ChinaUnited StatesUnited Kingdom
In The Last Decade
Bing Xu
178 papers receiving 3.2k citations
Bing Xu's Hit Papers
Peers
Comparison fields: 5 of 120
- Hematology 348
- Cancer Research 399
- Oncology 605
- Molecular Biology 1.4k
- Immunology 389
Countries citing papers authored by Bing Xu
This map shows the geographic impact of Bing Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bing Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bing Xu more than expected).
Fields of papers citing papers by Bing Xu
This network shows the impact of papers produced by Bing Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bing Xu. The network helps show where Bing Xu may publish in the future.
Co-authors
The 25 scholars most cited alongside Bing Xu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 199 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Disulfiram modulated ROS–MAPK and NFκB pathways and targeted breast cancer cells with cancer stem cell-like properties Hit paper breakdown → | 2011 | 360 |
| 2 | 2009 | 117 | |
| 3 | 2017 | 112 | |
| 4 | 2014 | 93 | |
| 5 | 2022 | 82 | |
| 6 | 2014 | 73 | |
| 7 | 2012 | 69 | |
| 8 | 2014 | 65 | |
| 9 | 2013 | 59 | |
| 10 | 2016 | 57 | |
| 11 | 2017 | 55 | |
| 12 | 2015 | 55 | |
| 13 | 2019 | 54 | |
| 14 | 2017 | 53 | |
| 15 | 2018 | 52 | |
| 16 | 2016 | 51 | |
| 17 | 2020 | 46 | |
| 18 | 2018 | 44 | |
| 19 | 2011 | 44 | |
| 20 | 2019 | 42 |
About Bing Xu
Bing Xu is a scholar working on Molecular Biology, Oncology, Hematology, Immunology and Cancer Research, having authored 199 papers that have together received 3.2k indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (21 papers), Histone Deacetylase Inhibitors Research (14 papers), Protein Degradation and Inhibitors (11 papers), Immune Cell Function and Interaction (11 papers), Cell death mechanisms and regulation (9 papers), CAR-T cell therapy research (9 papers), Lymphoma Diagnosis and Treatment (9 papers) and Acute Lymphoblastic Leukemia research (8 papers). The work is most often cited by research in Hematology (348 citations), Cancer Research (399 citations), Oncology (605 citations), Molecular Biology (1.4k citations) and Immunology (389 citations). Bing Xu has collaborated with scholars based in China, United States and United Kingdom. Frequent co-authors include Weiguang Wang, Angel L. Armesilla, John L. Darling, Vinodh Kannappan, Jie Zha, Manman Deng, Ning Dong, Nga Chi Yip, Julia Brown and J Cassidy. Their work appears in journals such as Blood, Oncotarget, Scientific Reports, Experimental Cell Research and Investigative Ophthalmology & Visual Science.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.